These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37728121)

  • 41. [Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile].
    Beneš J; Stebel R; Musil V; Krůtová M; Vejmelka J; Kohout P
    Klin Mikrobiol Infekc Lek; 2022 Sep; 28(3):77-94. PubMed ID: 36791303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.
    Kuehne SA; Dempster AW; Collery MM; Joshi N; Jowett J; Kelly ML; Cave R; Longshaw CM; Minton NP
    J Antimicrob Chemother; 2018 Apr; 73(4):973-980. PubMed ID: 29253242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fidaxomicin: in Clostridium difficile infection.
    Duggan ST
    Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
    Drugs R D; 2010; 10(1):37-45. PubMed ID: 20509714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
    Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
    Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin.
    Dorst A; Jung E; Gademann K
    Chimia (Aarau); 2020 Apr; 74(4):270-273. PubMed ID: 32331545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.
    Brauer M; Herrmann J; Zühlke D; Müller R; Riedel K; Sievers S
    Gut Pathog; 2022 Jan; 14(1):4. PubMed ID: 34991700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
    Monneret C
    Ann Pharm Fr; 2013 Mar; 71(2):95-103. PubMed ID: 23537410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
    Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats.
    Álvarez-Pérez S; Anega B; Blanco JL; Hernández M; García ME
    BMC Vet Res; 2023 Nov; 19(1):238. PubMed ID: 37974163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.
    Marchandin H; Anjou C; Poulen G; Freeman J; Wilcox M; Jean-Pierre H; Barbut F
    J Antimicrob Chemother; 2023 Aug; 78(8):1992-1999. PubMed ID: 37352110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L; Golan Y
    Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficilein vitro.
    Aldape MJ; Packham AE; Heeney DD; Rice SN; Bryant AE; Stevens DL
    J Med Microbiol; 2017 Oct; 66(10):1393-1399. PubMed ID: 28893366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
    Schwanbeck J; Riedel T; Laukien F; Schober I; Oehmig I; Zimmermann O; Overmann J; Groß U; Zautner AE; Bohne W
    J Antimicrob Chemother; 2019 Jan; 74(1):6-10. PubMed ID: 30247587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
    Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
    J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.